DANIEL VAUGHT: Open Payments
NPI 1609282482 · PUEBLO WEST, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,132 in 49 payments from 19 companies in 2025. Trend: 2023 $755 · 2024 $1,204 · 2025 $1,132
Food & beverage: $1,132
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $256 |
| ABBVIE INC. | 8 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $80 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $65 |
| Novo Nordisk Inc | 4 | $65 |
| Astellas Pharma US Inc | 2 | $54 |
| Amgen Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $40 |
Products named: VRAYLAR, FARXIGA, CAPLYTA, ZENPEP, Kerendia, Veozah, REXULTI, MOUNJARO.
Industry payments across CO — which companies pay providers there.
